Speech by the President of the Republic on scientific research.

France Emmanuel Macron · President of France

5 March 2023 · INRB

Context
Macron addressed scientists and diplomats at the INRB in Congo on March 5, 2023, to mark the signing of a new Franco-Congolese international research partnership in global health.
Main themes
Franco-Congolese scientific cooperation, INRB and Congolese research excellence, PRISM international research platform, global health partnerships, Ebola and emerging infectious diseases, One Health approach, zoonotic disease research, talent training and researcher mobility, biodiversity and pandemic preparedness, COVID-19 lessons, monkeypox research, France-Africa research diplomacy
Duration
~12 min
42nd percentile
Words
1,448
42nd percentile
Sentences
68
45th percentile
Readability
48
57th percentile
Grade
11.8
43rd percentile
Syntax
3.03
52nd percentile
Vocabulary
2.15
37th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 25%25%
  • Ceremonial 24%24%
  • Economic 18%18%
  • Geopolitical 15%15%
  • Environmental 9%9%
  • Technological 7%7%
  • Institutional 1%1%
  • Not in focus 1%

68 sentences in 20 paragraphs

Ladies and gentlemen ministers,

Professor,

Ladies and gentlemen ambassadors,

Ladies and gentlemen, in your ranks and capacities.

Everything has been said by the minister and the professor just now. I wanted to thank Professor MUYEMBE for the welcome at the INRB, this jewel of Congolese scientific research, and to thank him for the remarks he just made. Serendipity is indeed the marriage of chance and tenacity. And when we look at your journey and that of your laboratory, there may have been some chances. But we are convinced of one thing: there has been a lot of tenacity over time, a joyful and generous obstinacy in bringing together talents, training them, helping them grow, equipping you, weaving cooperations, and succeeding in building this true jewel here. So, I will not repeat what has been said. The primary objective was indeed to establish a form of the Pasteur Institute. And indeed, you placed your remarks under this auspice, which shows fidelity to this dream.

Then came the discovery of Ebola. The work that has been done. The work that then allowed us to reach monoclonal antibodies and the very concrete experiences of the processes. Then, along this path, the cooperation with France, the presence of President MITTERRAND in 1984, whose photo we saw just now, which sealed a friendship, an unprecedented cooperation. Even though 30 years ago, France ceased this cooperation due to political events, the link was never broken because many of your researchers, post-docs, and students, even for a few semesters, continued to be trained in France, particularly at the University of Montpellier. I was able to see this earlier when visiting the laboratory; a good part had passed through Montpellier. And so this link has persisted through training, exchanges, and the circulation of talents, but with the will to return. I did not see that for either them or you, these giant wings prevented you from walking. The Albatross thrives when it returns to the INRB and to Congo.

Beyond that, there is also the training of many researchers across the continent. I am told that there are at least seven Central African countries represented here with women and men who have passed through the National Institute of Public Health and who have thus learned here. It is true that there has been a bit less cooperation, at least, except for these training mechanisms, a different presence.

So we started to change things. You recalled it with the Franco-Congolese roadmap in health signed in 2019, which allowed us to engage in ambitious actions together to combat Ebola, strengthen the Congolese health system, and create new scientific partnerships. And this shared ambition allowed us to face together, by the way, the Covid-19 crisis, where you were on the front lines and where we were able to contribute to financing a sequencing laboratory that allowed you to work in real time and exchange work with ANRS and many other laboratories around the world.

But today, we are moving to a higher level. Indeed, a new page is opening with the International Research Platform in Global Health and this PRISM agreement. Through it, a new and ambitious partnership is being established between the INRB, four French scientific institutions, IRD, the University of Montpellier, ANRS, and Inserm, thus covering many areas and the themes of Ebola, monkeypox, Covid-19, and the therapeutic trials you yourself mentioned.

This step today and what you will do with it concretely allows us to return to the logic, if I may say, original. While having learned a lot collectively and thus doing even more and stronger, because fundamentally, we have learned some elements that, in my eyes, beyond today's signing, should guide our work.

First, as you said very well, all these viruses no longer have geographical borders. Whether they are regional or at the continental level. These viruses are now internationalizing in real time, and we have experienced this again recently. And so, an international cooperation of the highest level that complements the links you have with Belgium, Japan, and several other countries is relevant and strengthens the international character of a laboratory like yours.

The second thing is that there are no longer any borders between nature, animal species, and humans. We have experienced this as well. We talked about it earlier in the laboratory. It is highly likely that vibrant interaction spaces with such rich biodiversity will be the epicenters of future episodes of pathogenic zoonoses, even lethal to humans, and therefore it is important to strengthen the research sites at the forefront with the best equipment.

This philosophy - if I may say, of research - is familiar to you because it is your daily life, your knowledge - it may have been less so in national and international public health policies. And I believe that this is one of the elements we learned during Covid that led to what we called "One Health." For me, what will be done based on the partnership and the PRISM agreement is very illustrative of this One Health strategy that we have advocated for a little over two years, which we mentioned again in Libreville as part of the One Forest Summit. Understanding all these phenomena will be key, particularly the ability to make disciplines work together that have insufficiently communicated to understand the interactions between such a phenomenon of biodiversity, such an animal species, such a virus.

In this regard, as I said, the emergence or re-emergence of pathogenic zoonoses, even lethal to humans, is directly linked to what we are addressing today, and for that, I am very happy. You mentioned it, Mr. Minister, that the DRC joins the PREZODE initiative that we launched in 2021, which materializes the work of this type.

Lastly, we have also learned that there should no longer be a border between clinical research and the ability to translate the fastest possible responses on the ground from an epidemiological point of view in order to diagnose, treat, and care. This is essential if we want to eradicate viruses as soon as we identify them and do so in the right place, at the right time, with the right instruments. That is why, by sealing this new partnership and also recognizing your work over so many years, I want to emphasize the importance for us of two things that complement what we are discussing.

The first is to continue strengthening the primary health system of the DRC. Because doing everything we are doing with you today only makes sense if, when a new epidemic arises, we have the best capabilities to organize a vaccination campaign, to deploy responses. And so we need to double our efforts in parallel to have a primary health system throughout the territory that allows us to respond to the population as quickly and as closely as possible. We also need to have the right prevention policy.

The second thing is obviously to develop the capacities for production, treatments, diagnostic elements, medical devices, and vaccines on African territory. This is at the heart of what we launched in the spring of 2021 in South Africa, as well as in several other countries. This continent, which represents 20% of the global vaccine needs, produces 2%. As soon as there is an epidemic on a global scale, what we have already experienced happens: those who produce them keep them for themselves. Those who produce less are the last to be served. Can we legitimately consider that this is a fatality, that we should do nothing? No.

So we must also invest in capacities, not just for research but for the production of everything that is the fruit of the partnership research to which you will have contributed. Otherwise, the risk is that in two years, five years, ten years, perhaps you will have sequenced a virus here or contributed to its discovery? The Europeans, Americans, and Asians, the wealthiest, will have the ability to produce a vaccine very quickly, and you will only have it 6 or 12 months later. Therefore, we must also put ourselves together in a position to produce on African soil, in production hubs for vaccines that rely either on the technique of the dead virus or on messenger RNA technology. There is no fatality in investing.

These are the few convictions I wanted to bring beyond today's PRISM agreement, on what remains to be done in the months and years to come, with, I hope, the same tenacity as that which drives you, dear Professor, the same talent and the same humility.

Long live cooperation between the DRC and France! Long live this scientific cooperation and the excellence of your work.